Treatments for COPD may still leave you looking for relief from wheezing, coughing, and shortness of breath. That’s why Sanofi and Regeneron are researching the mechanism of action of an investigational medicine in former and current smokers who are between 40 and 70 years old with COPD.
This global, multicenter, phase 2a clinical trial (AERIFY 3) is an exploratory, two-part, 12-week study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) and its impact on airway inflammation. This study consists of participants who have been on a standard-of-care mono (long-acting β2-agonist [LABA] or long-acting muscarinic antagonist [LAMA]), double (inhaled corticosteroid [ICS] + LABA, LABA + LAMA, or ICS + LAMA), or triple (ICS + LABA + LAMA) controller therapy for COPD for at least 3 months prior to screening (Visit 1) with stable dose and regimen for controller therapy for ≥1 month prior to screening (Visit 1) and during the screening period. Participants will stay on their established controller medications for COPD throughout the duration of the study, with the exception of systemic corticosteroids and/or antibiotics used for acute exacerbation of COPD.
A number of clinical trial sites are available and recruiting patients across the United States. For additional information, or to learn if you might be eligible, please visit Sanofi Studies or ClinicalTrials.gov.